News

March 17, 2010 – New Results from PLATO trial suggest ticagrelor (Brilinta) leads to lower mortality and no increased risk of bleeding when compared to clopidogrel (Plavix) in patients with acute...

March 16, 2010 — Lowering blood pressure to normal levels — below currently recommended levels — did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events...

March 9, 2010 — An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac procedure such as a...

March 3, 2010 – Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to new market research from...

February 26, 2010 – The field of cardiovascular therapy is being transformed continuously due to the emergence of new anti-platelet agents possessing unique properties. During ACC 2010, the...

February 25, 2010 – Recent clinical studies of Ranexa, a prescription medication used to treat adults with chronic angina, indicate several positive benefits from treatment with this drug.

February 23, 2010 – Experts in anti-platelet therapy will offer their insights and interpretations on emerging agents in comparison to current therapy at an evening session during ACC 2010 from 6:...

February 19, 2010 – A chemical compound found normally in the blood has shown promise in treating and preventing an intractable form of heart failure in a mouse model of the disease, report...

February 9, 2010 – The FDA approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction and arterial revascularization procedures in individuals without clinically...

February 5, 2010 – A new, large-scale pivotal phase III trial has been initiated for edoxaban to evaluate its safety and efficacy in reducing recurrent venous thromboembolic (VTE) complications in...

January 22, 2010 - A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better. Instead, they...

January 21, 2010 – A new minimally invasive therapy using radiofrequency ablation to short-circuit nerves in the kidney arteries shows promise in treating uncontrolled hypertension. The research...

January 21, 2010 - A recent study found generic epoprostenol is a safe and effective therapy alternative to brand name Flolan for patients suffering from pulmonary arterial hypertension (PAH).

January 11, 2010 – A hypertension drug using a combination of telmisartan/amlodipine, which requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan), may earn 30 percent patient...

January 11, 2010 – The first patients were enrolled in the phase 3 clinical trials for a drug designed to lower triglycerides for patients at risk for cardiovascular disease.

January 7, 2010 – Doctors with Virginia Interventional and Vascular Associates (VIVA) report success in treating acute deep vein thrombosis (DVT) with a procedure called isolated...

January 7, 2010 – Anti-platelet treat with Effient (prasugrel) compared with Plavix (clopidogrel) was more cost effective, according to results from a health economic substudy of the TRITON-TIMI...

January 4, 2010 – The first patient was enrolled the TAXUS Liberte arm of the Dual Anti-Platelet Therapy (DAPT) Study, evaluating the TAXUS Liberté stent in combination with a dual anti-platelet...

December 30, 2009 – Medical device company Emerging Healthcare Solutions LLC (EHS) entered into an agreement to distribute ThromboVision’s T-Guide, a new diagnostic test to assess patient response...

December 24, 2009 – A clinical reference and pharmaceutical database application was released this week for the Google Android personal digital assistant (PDA) device.

December 23, 2009 – An investigational beta-blocker drug may be tested to see if it helps slow the progression of chronic heart failure in patients who have a specific genotype.

December 23, 2009 – The Cleveland Clinic this week initiated a phase II trial examining a new oral therapy for the treatment of atherosclerosis in patients with stable coronary artery disease (...

December 22, 2009 – A drug manufacturer recently filed paperwork with the FDA to produce a generic version of the cholesterol-lowering medication Vytorin.

December 21, 2009 – Revised guidelines on the use of beta-blockers for noncardiac surgery say therapy should neither be initiated on the day of surgery, nor stopped abruptly peri- or...

December 17, 2009 – The University of Virginia (UVa) in Charlottesville and AstraZeneca this week entered into a strategic research collaboration to enhance development of new treatments,...

December 16, 2009 – The FDA's Endocrinologic and Metabolic Drugs Advisory Committee yesterday agreed AstraZeneca established sufficient benefit with trial data showing prophylactic benefit of...

December 15, 2009 - The European Medicines Agency (EMEA) recently approved a new indication for Procoralan (ivabradine) for chronic, stable angina patients, who remain inadequately controlled...

December 14, 2009 – A new drug application (NDA) was recently submitted to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral anti-platelet treatment for the...

December, 14, 2009 – A supplemental new drug application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR, a cholesterol medication...

December 14, 2009 – First new anti-arrhythmic drug to be approved in the European Union in the last 10 years was recently granted European Commission marketing authorization.

December 10, 2009 – European approval was recently granted for the use of Angiox (bivalirudin) as an anti-coagulant in patients with ST-segment elevated myocardial infarction (STEMI) who...

November 18, 2009 — Results of preclinical studies with CXL-1020 demonstrate beneficial effects across the board on the treatment of acute decompensated heart failure (ADHF). All three major...

November 21, 2009 — A drug used to treat erectile dysfunction may improve heart function in children and young adults with single ventricle congenital heart disease, according to researchers from...

November 21, 2009 – The Food and Drug Administration (FDA) recently announced that it is reviewing data from a study suggesting patients using the drug sibutramine may have a higher number of...

November 23, 2009 – The U.S. Food and Drug Administration (FDA) Nov. 20 approved Revatio (sildenafil) Injection, an intravenous formulation of Revatio, for the treatment of adult patients with...

November 18, 2009 — A new, reversible blood thinner did not prove superior over placebo for its primary endpoints of heart attack and need for revascularization, but it did reduce in-stent blood...

November 18, 2009 – Three platelet function tests identified patients who will have blood cells that remain sticky, increasing heart attack risk, despite being pretreated with two anti-clotting...

November 18, 2009 – Patient enrollment was recently completed in the TRA 2 P-TIMI 50 clinical trial to study SCH 530348, an investigational anti-platelet protease activated receptor-1 (PAR-1)...

November 18, 2009 – New, joint guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI...

November 17, 2009 – The U.S. Food and Drug Administration (FDA) today warned new safety information shows an interaction between the anti-clotting medication clopidogrel (Plavix) and the proton...

November 13, 2009 – A new study, published in the Nov. 17, 2009 issue of the Journal of the American College of Cardiology, adds to a growing body of research seeking to evaluate and understand...

November 2, 2009 — Cardiac complications around the time of noncardiac surgery are relatively common and can be serious.

October 29. 2009 – Results of the SLIM Study ("Slo-Niacin and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of...

October 21, 2009 – King Pharmaceuticals Inc. said today the U.S. Food and Drug Administration issued a complete response letter regarding the new drug application (NDA) for its cardiac...

October 19, 2009 – Boehringer Ingelheim Pharmaceuticals Inc.

October 16, 2009 – AstraZeneca yesterday said the U.S. Food and Drug Administration cleared CRESTOR (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial...

October 15, 2009 – A study conducted by the University of Rochester Medical Center (URMC) demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may...

October 12, 2009 – Daiichi Sankyo Inc. (DSI) last week said the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application for Welchol (colesevelam HCl) for children...

October 9, 2009 – CardioPharma is beginning the final funding phase before submitting an FDA new drug application (NDA) for CardiaPill, the world's first patented triple-combination cardiovascular...

October 8, 2009 – In a recent survey of more than 2,000 U.S. physicians conducted by Epocrates Inc., cardiologists and other specialists shared their perspective on the latest patient visit trends...

October 6, 2009 – The Harvard Clinical Research Institute (HCRI) said last week the first patients are enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial...

October 5, 2009 – A reduction in stroke was observed in patients with atrial fibrillation (AF) who received dronedarone (MULTAQ), according to a recent study published online in Circulation – “...

October 5, 2009 – A new analysis reaffirms that Lexiscan (regadenoson) Injection, the first selective A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in...

September 28, 2009 – New data from the phase III PLATO study showed that ticagrelor (BRILINTA) provided 16 percent reduction of cardiovascular (CV) events (composite of CV death, heart attack and...

September 28, 2009 – Sanofi-aventis announced last week the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion...

September 18, 2009 – Patients’ response to anti-platelet therapy after percutaneous coronary intervention (PCI) and its impact on clinical outcomes will be covered in a TCT 2009 breakfast...

September 18, 2009 – The FDA has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin...

September 17, 2009 – The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) on Wednesday featured four late breaking clinical trials.

September 14, 2009 – The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes Convention Center in Boston....

Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in interventional cardiology that will be presented during the Transcatheter...

September 10, 2009 – Regado Biosciences said this week it enrolled the first patient in a phase 2b, randomized, partially-blinded, multicenter, active-controlled, dose-ranging study of its REG1...

September 8, 2009 – Actelion Pharmaceuticals U.S. Inc. recently announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis, for the treatment of...

September 3, 2009 – Important new findings in patients with angina participating in the BEAUTIFUL study show that there is a 42 percent reduction in heart attack with Procoralan (ivabradine), as...

September 3, 2009 – The OASIS study group presented initial results of the CURRENT-OASIS 7 clinical trial Sunday at the European Society of Cardiology Congress in Barcelona, which did not show a...

September 2, 2009 – A new analysis from the JUPITER study showed CRESTOR (rosuvastatin calcium) 20 mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial...

September 1, 2009 – Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take...

September 1, 2009 – Sanofi-aventis said Sunday the investigational anti-Xa intravenous anti-coagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death,...

September 1, 2009 – AstraZeneca last week announced results from the phase III head to head trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that ticagrelor (...

August 13, 2009 – Abbott today announced the expansion of the company's XIENCE V USA post-approval study designed to evaluate the safety and effectiveness of the company's XIENCE V Everolimus-...

August 13, 2009 – The pharmaceutical and healthcare research firm Decision Resources found Merck/Schering-Plough's Zetia and Vytorin lost substantial patient share in second- and third-line...

August 10, 2009 – Health Care Service Corp. (HCSC), which operates the Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas, is expanding a successful new cholesterol...

August 6, 2009 – Palatin Technologies Inc. said this week it received a notice of allowance from the U.S. Patent and Trademark Office covering a family of cyclic compounds that bind to natriuretic...

August 6, 2009 – Merck & Co. Schering-Plough Corp. and the companies' cholesterol joint venture, Merck/Schering-Plough Pharmaceuticals (MSP), this week announced they entered into agreements...

August 5, 2009 – Nile Therapeutics Inc. said this week it dosed its first patient in a phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure.

August 4, 2009 – Watson Pharmaceuticals Inc. said this week it received FDA approval on its abbreviated new drug applications (ANDAs) for metoprolol succinate extended-release tablets USP in the...